Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 6/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 5/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29664506 | 1.00 | TYR (0.50) | TYRCHRNA7ESR1ESR2ALOX5 | |
| SCHEMBL2767004 | 0.82 | CHRNA7 (0.53) | TYRCHRNA7ESR1ESR2ALOX5 | |
| SCHEMBL13614613 | 0.81 | TYR (0.50) | TYRCHRNA7ESR1ESR2ALOX5 | |
| SCHEMBL4678542 | 0.81 | TYR (0.44) | TYRCHRNA7ESR1ESR2ALOX5 | |
| SCHEMBL647503 | 0.80 | TYR (0.68) | TYRALOX5MEN1MAPTKMT2A | |
| SCHEMBL11306662 | 0.79 | TYR (0.48) | TYRCHRNA7ESR1ESR2ALOX5 | |
| SCHEMBL28757491 | 0.79 | CHRNA7 (0.50) | TYRCHRNA7ESR1ESR2ALOX5 | |
| SCHEMBL310196 | 0.79 | CHRNA7 (0.50) | TYRCHRNA7ESR1ESR2ALOX5 | |
| SCHEMBL14446348 | 0.79 | TYR (0.48) | TYRCHRNA7ESR1ESR2ALOX5 | |
| SCHEMBL4959085 | 0.79 | TYR (0.48) | TYRCHRNA7ESR1ESR2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120081885-A | Substituted phenyl glycoside compound and preparation method and application thereof | 浙江大学 | 2025-06-03 | — | — | CN | claimed |
| CN-113736349-B | Corrosion-resistant epoxy resin coating and preparation method thereof | 安徽华辉塑业科技股份有限公司 | 2022-05-17 | — | — | CN | claimed |
| CN-113736349-A | Corrosion-resistant epoxy resin coating and preparation method thereof | 安徽华辉塑业科技股份有限公司 | 2021-12-03 | — | — | CN | claimed |
| CN-111162313-A | Polymer electrolyte and lithium ion battery | 珠海冠宇电池有限公司 | 2020-05-15 | — | — | CN | claimed |
| CN-120081885-A | Substituted phenyl glycoside compound and preparation method and application thereof | 浙江大学 | 2025-06-03 | — | — | CN | disclosed |
| CN-119032076-A | Novel compounds and uses thereof | 株式会社安提昂 | 2024-11-26 | — | — | CN | disclosed |
| US-12049444-B2 | Monomethyl fumarate precursor drug compounds and pharmaceutical compositions thereof | AGATHONBIO CO., LTD. (KR) | 2024-07-30 | — | — | US | disclosed |
| US-20230416460-A1 | COMPOUND, RESIN COMPOSITION, RESIN SHEET, RESIN CURED PRODUCT, AND LAMINATED SUBSTRATE | TDK CORPORATION (JP) | 2023-12-28 | — | — | US | disclosed |
| WO-2023239171-A1 | NOVEL COMPOUND AND USE THEREOF | 주식회사 엑티브온 | 2023-12-14 | — | — | WO | disclosed |
| CN-116490355-A | Compound, resin composition, resin sheet, resin cured product, and laminated substrate | TDK株式会社 | 2023-07-25 | — | — | CN | disclosed |
| WO-2022209495-A1 | COMPOUND, RESIN COMPOSITION, RESIN SHEET, RESIN CURED OBJECT, AND LAMINATED SUBSTRATE | TDK株式会社 | 2022-10-06 | — | — | WO | disclosed |
| CN-113736349-B | Corrosion-resistant epoxy resin coating and preparation method thereof | 安徽华辉塑业科技股份有限公司 | 2022-05-17 | — | — | CN | disclosed |
| EP-1343775-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-17 | — | — | EP | disclosed |
| WO-2001020995-A9 | COMPOUNDS DIRECTED AGAINST PILUS BIOGENESIS AND ACTIVITY IN PATHOGENIC BACTERIA; METHODS AND COMPOSITIONS FOR SYNTHESIS THEREOF | UNIV WASHINGTON (US) | 2002-11-14 | — | — | WO | disclosed |
| US-20020143020-A1 | Novel piperazine derivatives | VERNALIS RESEARCH LIMITED (GB) | 2002-10-03 | — | — | US | disclosed |
| WO-2002048124-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-20 | — | — | WO | disclosed |
| WO-2001020995-A1 | COMPOUNDS DIRECTED AGAINST PILUS BIOGENESIS AND ACTIVITY IN PATHOGENIC BACTERIA; METHODS AND COMPOSITIONS FOR SYNTHESIS THEREOF | WASHINGTON UNIVERSITY (US) | 2001-03-29 | — | — | WO | disclosed |
| CN-1284165-A | Method and reagents for quantification of solid-phase reactions using fluorine NMR | AVENTISS PHARMACEUTICAL PRODUC (US) | 2001-02-14 | — | — | CN | disclosed |
| EP-1044364-A1 | METHOD AND REAGENTS FOR THE QUANTIFICATION OF SOLID-PHASE REACTIONS USING FLUORINE NMR | Aventis Pharmaceuticals Products Inc. (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999031491-A1 | METHOD AND REAGENTS FOR THE QUANTIFICATION OF SOLID-PHASE REACTIONS USING FLUORINE NMR | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143020-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | TYR 2383/4885CHRNA7 3203/4885ESR1 2206/4885 |
| US-12049444-B2 | Monomethyl fumarate precursor drug compounds and pharmaceutical compositions thereof | FH, FPGS, FAH | TYR 4110/4885CHRNA7 4232/4885ESR1 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.